Literature DB >> 27341986

Value of pretherapeutic DWI in evaluating prognosis and therapeutic effect in immunocompetent patients with primary central nervous system lymphoma given high-dose methotrexate-based chemotherapy: ADC-based assessment.

Y Zhang1, Q Zhang1, X-X Wang2, X-F Deng3, Y-Z Zhu4.   

Abstract

AIM: To investigate apparent diffusion coefficient (ADC) as a prognostic indicator in primary central nervous system lymphoma (PCNSL) by analysing patient clinical characteristics and pretherapeutic diffusion-weighted imaging (DWI).
MATERIALS AND METHODS: Clinical characteristics and pretherapeutic DWI were studied retrospectively in 28 patients receiving high-dose methotrexate (HD-MTX)-based chemotherapy. Mean (ADCmean), 95th percentile (ADC95%), and 5th percentile (ADC5%) ADC values of the enhancing tumour volume were measured. The influence of prognostic parameters on progression-free survival (PFS) was investigated by log-rank test and Cox regression analysis. Correlations between the variables and PFS or the level of Ki-67 expression were analysed. ADC and clinical features were analysed using an independent sample t-test between the complete response (CRi) and partial response (PRi) groups after initial four cycles of chemotherapy. Receiver operating characteristic (ROC) curves were constructed using ADC parameters.
RESULTS: Patients with CRi, lower Ki-67 level, higher Karnofsky performance status (KPS), ADC5%, or ADCmean showed better PFS. The level of Ki-67 expression and ADC5% were independent risk factors. There was a positive correlation between KPS, ADC5%, and PFS, and negative correlation between ADC5%, PFS, and the level of Ki-67 expression. There was a significant difference for PFS, KPS, ADCmean, and ADC5% between CRi and non-CRi; however, ADC5% outperformed ADCmean because the area under the ROC curve (AUC) using ADC5% (0.983) was higher than the AUC using ADCmean (0.822).
CONCLUSION: ADC measurements, especially ADC5%, are useful predictors for PFS and response to HD-MTX in PCNSL.
Copyright © 2016 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27341986     DOI: 10.1016/j.crad.2016.05.017

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  9 in total

1.  Diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging after radiation therapy for bone metastases in patients with hepatocellular carcinoma.

Authors:  Ji Hyun Lee; Gyu Sang Yoo; Young Cheol Yoon; Hee Chul Park; Hyun Su Kim
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.379

2.  Associations between apparent diffusion coefficient (ADC) and KI 67 in different tumors: a meta-analysis. Part 2: ADCmin.

Authors:  Alexey Surov; Hans Jonas Meyer; Andreas Wienke
Journal:  Oncotarget       Date:  2018-01-04

3.  Associations between apparent diffusion coefficient (ADC) and KI 67 in different tumors: a meta-analysis. Part 1: ADCmean.

Authors:  Alexey Surov; Hans Jonas Meyer; Andreas Wienke
Journal:  Oncotarget       Date:  2017-08-24

4.  Whole Tumor Histogram Analysis Using DW MRI in Primary Central Nervous System Lymphoma Correlates with Tumor Biomarkers and Outcome.

Authors:  Insun Chong; Quinn Ostrom; Bilal Khan; Dima Dandachi; Naveen Garg; Aikaterini Kotrotsou; Rivka Colen; Fanny Morón
Journal:  Cancers (Basel)       Date:  2019-10-08       Impact factor: 6.639

5.  Branch-like enhancement on contrast enhanced MRI is a specific finding of cerebellar lymphoma compared with other pathologies.

Authors:  Kota Yokoyama; Jun Oyama; Junichi Tsuchiya; Jun Karakama; Kaoru Tamura; Motoki Inaji; Yoji Tanaka; Daisuke Kobayashi; Taketoshi Maehara; Ukihide Tateishi
Journal:  Sci Rep       Date:  2022-03-04       Impact factor: 4.379

6.  Primary central nervous system lymphoma: advances in MRI and PET imaging.

Authors:  Prakash Ambady; Leland S Hu; Letterio S Politi; Nicoletta Anzalone; Ramon F Barajas
Journal:  Ann Lymphoma       Date:  2021-09-30

7.  Performance of diffusion and perfusion MRI in evaluating primary central nervous system lymphomas of different locations.

Authors:  Zhen Xing; Nannan Kang; Yu Lin; Xiaofang Zhou; Zebin Xiao; Dairong Cao
Journal:  BMC Med Imaging       Date:  2020-06-09       Impact factor: 1.930

Review 8.  Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring.

Authors:  C Chiavazza; A Pellerino; F Ferrio; A Cistaro; R Soffietti; R Rudà
Journal:  Biomed Res Int       Date:  2018-06-21       Impact factor: 3.411

Review 9.  On point in primary CNS lymphoma.

Authors:  Mazie Tsang; Joseph Cleveland; James L Rubenstein
Journal:  Hematol Oncol       Date:  2020-07-03       Impact factor: 5.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.